Studies conducted by Cheng et al., Peng et al., and Kopetz et al. examined the relationship between gut microbiome composition and the response to anti-PD-1/PD-L1 immunotherapy in colorectal cancer patients following the RECIST 1.1. Here, CD274 is linked to colorectal cancer.